NPA 32nd Annual Psychopharmacology Update 2027: Program & Speakers

Mariely Hernandez, PhD

How ADHD and substance use intersect in women, with guidance on recognition, risk assessment, and treatment planning.

C. Neill Epperson, MD

Evaluation and management of mood disorders linked to the menstrual cycle, including premenstrual exacerbations and PMDD.

Simone Vigod, MD

Prescribing psychotropics during pregnancy and breastfeeding, weighing fetal and infant exposure against the risks of untreated illness.

Benicio N. Frey, MD, PhD

Postpartum psychiatric presentations beyond depression, including anxiety, OCD, and psychosis, and how to treat them.

Claudio N. Soares, MD, PhD

Mood and anxiety symptoms during perimenopause and menopause, with hormonal and psychopharmacologic treatment options.

Claudio N. Soares, MD, PhD

Sleep disturbance and cognitive complaints across the menopause transition and evidence-based approaches to managing them.

Jennifer Swainson, MD

Adjusting psychotropic selection and dosing for older women, accounting for age-related pharmacokinetic and hormonal changes.

Jewel M. Kling, MD, MPH

Assessment and management of female sexual dysfunction in psychiatric practice, including medication-related contributors.

Scott Aaronson, MD

Accelerated TMS protocols and other rapid-acting neuromodulation strategies for depression.

Scott Aaronson, MD

Where psychedelic-assisted treatment stands for severe treatment-resistant depression, from trial evidence to practical considerations.

J. Michael Bostwick, MD

Diagnosis of prolonged grief disorder and the psychotherapies and medications with evidence for it.

J. Michael Bostwick, MD

Clinical, ethical, and legal issues psychiatrists face around medical aid in dying, including capacity assessment.

Louisa Sylvia, PhD

Using rating scales and measurement-based care to guide diagnosis and treatment decisions in bipolar disorder.

Mark Zimmerman, MD

Managing comorbid anxiety in mood disorders, where standard anxiolytic strategies can complicate treatment.

Katharine Phillips, MD

Recognition of body dysmorphic disorder and its evidence-based treatment with SSRIs and CBT.

Kimberly Nordstrom, MD, JD

Pharmacologic management of agitation and other psychiatric emergencies in acute settings.

Richard Kogan, MD

Concert-lecture exploring the relationship between psychiatric illness and musical creativity through the lives of famous composers.

Jeffrey Strawn, MD

Evidence-based pharmacologic and psychotherapeutic treatment of pediatric anxiety disorders.

Manpreet Singh, MD

Current approaches to treating depression and bipolar disorder in youth.

Jeffrey Newcorn, MD

The evidence for digital therapeutics in ADHD and how they fit alongside medication across the lifespan.

Esther Dechant, MD

Practical management of anorexia nervosa, bulimia nervosa, and binge-eating disorder, including the pharmacologic options.

Mark Rapaport, MD

What the evidence supports among complementary and integrative treatments in psychiatry.

Roger McIntyre, MD

The glutamate hypothesis of depression and its therapeutic implications, from ketamine to emerging agents.

Roger McIntyre, MD

Where GLP-1 receptor agonists fit in psychiatric practice, from antipsychotic-associated weight gain to emerging behavioral indications.

Shashank Joshi, MD

Risk assessment and prevention strategies for suicidality in children and adolescents.

Jose Maldonado, MD

Recognition, workup, and management of delirium, including when and how to use antipsychotics.

Dylan Wint, MD

Recent advances in dementia therapeutics, including anti-amyloid agents and symptomatic management.

Eleasa Sokolski, MD

Current pharmacologic and behavioral strategies for methamphetamine use disorder.

Robert Cotes, MD

How clozapine prescribing and hematologic monitoring change after the end of the REMS program.

Alon Avidan, MD

Diagnosis and treatment of common sleep disorders in psychiatric patients, including insomnia pharmacotherapy.

Christopher Celano, MD

Safe psychotropic prescribing in cardiac disease, including QTc and drug-interaction considerations.

Kenneth Rosenberg, MD

Assessment and treatment of compulsive sexual behavior in psychiatric practice.

Dan Roden, MD

What pharmacogenomic testing can and cannot tell us when selecting and dosing psychotropics.